- Home
- GDEN vs AUTL Comparison
GDEN vs AUTL Comparison
Compare GDEN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- AUTL
- Stock Information
- Founded
- GDEN 1998
- AUTL 2014
- Country
- GDEN United States
- AUTL United Kingdom
- Employees
- GDEN N/A
- AUTL N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDEN Consumer Discretionary
- AUTL Health Care
- Exchange
- GDEN Nasdaq
- AUTL Nasdaq
- Market Cap
- GDEN 727.9M
- AUTL 625.4M
- IPO Year
- GDEN 1999
- AUTL 2018
- Fundamental
- Price
- GDEN $24.80
- AUTL $1.46
- Analyst Decision
- GDEN Buy
- AUTL Strong Buy
- Analyst Count
- GDEN 7
- AUTL 5
- Target Price
- GDEN $34.86
- AUTL $9.12
- AVG Volume (30 Days)
- GDEN 224.9K
- AUTL 3.8M
- Earning Date
- GDEN 11-06-2025
- AUTL 08-12-2025
- Dividend Yield
- GDEN 4.03%
- AUTL N/A
- EPS Growth
- GDEN N/A
- AUTL N/A
- EPS
- GDEN 0.54
- AUTL N/A
- Revenue
- GDEN $649,900,000.00
- AUTL $29,934,000.00
- Revenue This Year
- GDEN N/A
- AUTL $634.25
- Revenue Next Year
- GDEN $2.29
- AUTL $93.16
- P/E Ratio
- GDEN $45.84
- AUTL N/A
- Revenue Growth
- GDEN N/A
- AUTL 185.17
- 52 Week Low
- GDEN $22.66
- AUTL $1.11
- 52 Week High
- GDEN $35.49
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- GDEN 40.85
- AUTL 27.33
- Support Level
- GDEN $23.95
- AUTL $1.39
- Resistance Level
- GDEN $25.49
- AUTL $1.55
- Average True Range (ATR)
- GDEN 0.60
- AUTL 0.10
- MACD
- GDEN 0.11
- AUTL -0.02
- Stochastic Oscillator
- GDEN 45.45
- AUTL 14.00
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.